Retagliptin

DB14898InvestigationalSmall molecule

Retagliptin is under investigation in clinical trial NCT02822534 (The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients).

Formula / weight: C₁₉H₁₈F₆N₄O₃ · 464.368 g/mol (avg)
Code names: SP2086

Resolves to

Compound

UNII328C4R3P9LCAS1174122-54-3

Structure

InChIKeyWIIAMRXFUJLYEF-SNVBAGLBSA-NSMILESCOC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F

Targets

P27487DPP4

What you can answer from here — as of November 18, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Retagliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account